FDA Commissioner Marty Makary Resigns Amid Pressure
Published on 5/12/2026

AI Summary
FDA Commissioner Marty Makary has resigned from his position. His departure comes amid reported pressures related to the Trump administration. The implications of this resignation on FDA operations remain unclear, but it may affect regulatory processes involved in drug approvals and public health initiatives. This situation could have a potential impact on pharmaceutical stocks and investor sentiment regarding the FDA's regulatory environment.
Related News

Regulation
Abbott Laboratories (ABT) Faces Class-Action Lawsuit Over PediaSure
Jun 27

HealthTech
NeuroPace (NPCE) Receives FDA Approval for ECoG Assistant™
Jun 27

Regulation
UK Government Debates New ‘Golden Visa’ Scheme Amid Corruption Concerns
Jun 27

Regulation
US Court Rejects EPA Bid on Coal Regulations Impacting Markets
Jun 27